BiotechTube

Camostat Mesylate + Microcrystalline Cellulose, NF

Phase 1/2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Coagulopathy

Conditions

Coagulopathy, Cardiovascular Complication, COVID-19

Trial Timeline

Nov 1, 2021 → Dec 31, 2021

NCT ID
NCT04435015

About Camostat Mesylate + Microcrystalline Cellulose, NF

Camostat Mesylate + Microcrystalline Cellulose, NF is a phase 1/2 stage product being developed by Ono Pharmaceutical for Coagulopathy. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04435015. Target conditions include Coagulopathy, Cardiovascular Complication, COVID-19.

What happened to similar drugs?

1 of 2 similar drugs in Coagulopathy were approved

Approved (1) Terminated (0) Active (1)
✅Fibrinogen concentrate + Fresh Frozen PlasmaCSLApproved
🔄Beriplex® P/N (Kcentra) + Fresh frozen plasmaCSLPhase 3

Hype Score Breakdown

Clinical
9
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04435015Phase 1/2Withdrawn

Competing Products

2 competing products in Coagulopathy

See all competitors
ProductCompanyStageHype Score
Beriplex® P/N (Kcentra) + Fresh frozen plasmaCSLPhase 3
40
Fibrinogen concentrate + Fresh Frozen PlasmaCSLApproved
43